Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter March 5, 2010

Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall

  • Niklas Mattsson , Kaj Blennow and Henrik Zetterberg

Abstract

Several drug candidates for Alzheimer's disease are being evaluated in clinical trials, with the goal of finding a drug with disease-modifying effects. When such a drug finally reaches the market, there will be a demand for accurate diagnostic tools useful for early detection of disease and for monitoring biochemical effects. The core cerebrospinal fluid (CSF) biomarkers amyloid peptides (Aβ42), total-tau and phospo-tau are promising in this respect. However, inter-center variation (caused by pre-analytical, analytical and post-analytical factors), and inter-laboratory variation (caused by analytical factors), particularly for CSF Aβ42, lowers their utility in multicenter studies. Here, we discuss the causes of these variations, and present a global quality control program to overcome them.

Clin Chem Lab Med 2010;48:603–7.


Corresponding author: Dr. Niklas Mattsson, Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital/Mölndal, 431 80 Mölndal, Sweden Phone: +46 31 3432377, Fax: +46 31 3432426,

Received: 2009-11-6
Accepted: 2010-1-8
Published Online: 2010-03-5
Published in Print: 2010-05-01

©2010 by Walter de Gruyter Berlin New York

Downloaded on 28.3.2024 from https://www.degruyter.com/document/doi/10.1515/CCLM.2010.131/html
Scroll to top button